PURPOSE: Glioma-associated oncogene family zinc finger 1 (GLI1) expression was assessed to determine a potential role of hedgehog (Hh) signaling in head and neck squamous cell carcinoma (HNSCC). Additional proteins known to be modulated by Hh signaling, including beta-catenin (CTNNB1) and epidermal growth factor receptor (EGFR), were also assessed to determine the correlation among these distinct signaling pathways. PATIENTS AND METHODS: Nuclear GLI1 and CTNNB1 expression levels were determined in tumors from patients enrolled on Radiation Therapy Oncology Group (RTOG) 9003, a radiation fractionation trial. The results were also correlated with previously determined EGFR expression. The expression levels were evaluated in relation to three end points: time to metastasis (TTM), time to disease progression (TDP), and overall survival (OS). RESULTS: Among 1,068 eligible patients, data on GLI1, CTNNB1, and EGFR were available in 339, 164, and 300 patients, respectively. Although CTNNB1 expression did not differentiate prognosis, GLI1 was associated with poorer outcomes, adjusted for age, TNM stages, and Karnofsky performance score, and the significant influence persisted in a multivariable analysis (quartile 4 [Q4] v Q1 to Q3: TTM hazard ratio [HR], 2.7; 95% CI, 1.5 to 4.9; TDP HR, 1.6; 95% CI, 1.1 to 2.5; OS HR, 1.9; 95% CI, 1.4 to 2.7). The significance of GLI1 persisted in a multivariable analysis that included EGFR expression levels. CONCLUSION: These data suggest that Hh signaling may play an important role in metastasis and that GLI1 could serve as a marker in HNSCC, but the regulatory mechanisms and oncogenic significance need further investigation. Risk classification based on this analysis needs a validation in independent cohorts.
PURPOSE:Glioma-associated oncogene family zinc finger 1 (GLI1) expression was assessed to determine a potential role of hedgehog (Hh) signaling in head and neck squamous cell carcinoma (HNSCC). Additional proteins known to be modulated by Hh signaling, including beta-catenin (CTNNB1) and epidermal growth factor receptor (EGFR), were also assessed to determine the correlation among these distinct signaling pathways. PATIENTS AND METHODS: Nuclear GLI1 and CTNNB1 expression levels were determined in tumors from patients enrolled on Radiation Therapy Oncology Group (RTOG) 9003, a radiation fractionation trial. The results were also correlated with previously determined EGFR expression. The expression levels were evaluated in relation to three end points: time to metastasis (TTM), time to disease progression (TDP), and overall survival (OS). RESULTS: Among 1,068 eligible patients, data on GLI1, CTNNB1, and EGFR were available in 339, 164, and 300 patients, respectively. Although CTNNB1 expression did not differentiate prognosis, GLI1 was associated with poorer outcomes, adjusted for age, TNM stages, and Karnofsky performance score, and the significant influence persisted in a multivariable analysis (quartile 4 [Q4] v Q1 to Q3: TTM hazard ratio [HR], 2.7; 95% CI, 1.5 to 4.9; TDP HR, 1.6; 95% CI, 1.1 to 2.5; OS HR, 1.9; 95% CI, 1.4 to 2.7). The significance of GLI1 persisted in a multivariable analysis that included EGFR expression levels. CONCLUSION: These data suggest that Hh signaling may play an important role in metastasis and that GLI1 could serve as a marker in HNSCC, but the regulatory mechanisms and oncogenic significance need further investigation. Risk classification based on this analysis needs a validation in independent cohorts.
Authors: D Neil Watkins; David M Berman; Scott G Burkholder; Baolin Wang; Philip A Beachy; Stephen B Baylin Journal: Nature Date: 2003-03-05 Impact factor: 49.962
Authors: Christine H Chung; Qiang Zhang; Elizabeth M Hammond; Andy M Trotti; Huijun Wang; Sharon Spencer; Hua-Zhong Zhang; Jay Cooper; Richard Jordan; Marvin H Rotman; K Kian Ang Journal: Int J Radiat Oncol Biol Phys Date: 2010-08-21 Impact factor: 7.038
Authors: David M Berman; Sunil S Karhadkar; Andrew R Hallahan; Joel I Pritchard; Charles G Eberhart; D Neil Watkins; James K Chen; Michael K Cooper; Jussi Taipale; James M Olson; Philip A Beachy Journal: Science Date: 2002-08-30 Impact factor: 47.728
Authors: K Kian Ang; Brian A Berkey; Xiaoyu Tu; Hua-Zhong Zhang; Ruth Katz; Elizabeth H Hammond; Karen K Fu; Luka Milas Journal: Cancer Res Date: 2002-12-15 Impact factor: 12.701
Authors: Alexandra Lucs; Benjamin Saltman; Christine H Chung; Bettie M Steinberg; David L Schwartz Journal: Head Neck Date: 2012-01-27 Impact factor: 3.147
Authors: Stephen G Chun; Hyunsil Park; Raj K Pandita; Nobuo Horikoshi; Tej K Pandita; David L Schwartz; John S Yordy Journal: Am J Cancer Res Date: 2015-03-15 Impact factor: 6.166
Authors: Gregory N Gan; Justin Eagles; Stephen B Keysar; Guoliang Wang; Magdalena J Glogowska; Cem Altunbas; Ryan T Anderson; Phuong N Le; J Jason Morton; Barbara Frederick; David Raben; Xiao-Jing Wang; Antonio Jimeno Journal: Cancer Res Date: 2014-10-08 Impact factor: 12.701
Authors: Daniel W Bowles; Stephen B Keysar; Justin R Eagles; Guoliang Wang; Magdalena J Glogowska; Jessica D McDermott; Phuong N Le; Dexiang Gao; Charles E Ray; Paul J Rochon; Dennis R Roop; Aik-Choon Tan; Hilary S Serracino; Antonio Jimeno Journal: Oral Oncol Date: 2015-12-15 Impact factor: 5.337